Prospective, monocentric study aiming to identify factors involved in platinum based-chemotherapy resistance in patients with epithelial ovarian cancer (all stages). Patients will receive treatment (platinum based-chemotherapy) according to the standard practices. A prospective database and an associated biological collection will be performed during 5 years: * For each patient: clinical, biological, epidemiological and therapeutic treatment data will be collected during the standard therapeutic care. * Biological samples (blood samples, tumor biopsy specimens and ascites samples) will be collected for all patients. These samples will be collected at the same time as those taken in standard practice (no additional biopsy will be performed for the study). Study participation of each patient will be 5 years.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
600
Blood samples, tumor biopsy specimens and ascites samples will be collected at different time points (if feasible, according to the samples taken in the standard practice): * before treatment initiation (blood sample), * during hospitalisation for surgery (blood sample), * during follow-up consultations (blood sample). If tumor biopsy and/or ascites sampling are performed during the standard care, a sample will be collected for the study.
Institut Universitaire du Cancer de Toulouse - Oncopole
Toulouse, France
RECRUITINGThe rate of patients alive without progression
Time frame: 5 years for each patient
The time to onset of platinum based-chemotherapy resistance
Time frame: 5 years for each patient
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.